This course has expired. View available courses.
Oncology
ESMO in Focus: Targeting rare oncogenes and kinase inhibitor resistant tumours
Four leading Australian experts, Prof Kenneth O'Byrne, Prof Duncan Topliss, Dr Malinda Itchins and Prof Sandra O'Toole, discuss presentations from the 2021 European Society of Medical Oncology (ESMO) meeting on the evolving landscape of genetic testing and treatment for rare fusion oncogene mutation associated thyroid and lung cancers, focusing on RET fusion positive cancers.
Professor Topliss presents a survey of the panorama of genomic RET mutations in the major thyroid cancer subtypes, studies of molecular genotyping practices and treatment protocols in refractory thyroid cancers across Europe and data from LIBRETTO-531 comparing selpercatinib to standard of care in advanced/metastatic MTC.
Dr Itchins presents data on improved outcomes in patients with ALK-rearranged NSCLC treated with alectinib and promising early data for selective RET inhibitors in frontline treatment of RET fusion positive NSCLC: selpercatinib in LIBRETTO-001 and pralsetinib in ARROW.
The discussion covers development of next generation RET inhibitors, active against a broad array of resistance mutations, LIBRETTO 432 investigating peri-operative selpercatinib and novel therapeutic approaches including novel antibody drug conjugates to combat drug resistance, novel biospecific antibodies and the role of combination therapy.
Professor O’Toole reviews fusion oncogene testing technology, practices and availability in Australia, and the experts discuss technical, logistic and financial barriers to testing and expected future developments.
This program is supported by an independent and unrestricted educational grant by EliLilly
DURATION
1 hr
PROFESSION
Specialist
# OF CREDITS
0
ACCREDITATION
Unaccredited
EXPIRY DATE
2022-11-22
Four leading Australian experts, Prof Kenneth O’Byrne, Prof Duncan Topliss, Dr Malinda Itchins and Prof Sandra O’Toole, discuss presentations from the 2021 European Society of Medical Oncology (ESMO) meeting on the evolving landscape of genetic testing and treatment for rare fusion oncogene mutation associated thyroid and lung cancers, focusing on RET fusion positive cancers.
Professor Topliss presents a survey of the panorama of genomic RET mutations in the major thyroid cancer subtypes, studies of molecular genotyping practices and treatment protocols in refractory thyroid cancers across Europe and data from LIBRETTO-531 comparing selpercatinib to standard of care in advanced/metastatic MTC.
Dr Itchins presents data on improved outcomes in patients with ALK-rearranged NSCLC treated with alectinib and promising early data for selective RET inhibitors in frontline treatment of RET fusion positive NSCLC: selpercatinib in LIBRETTO-001 and pralsetinib in ARROW.
The discussion covers development of next generation RET inhibitors, active against a broad array of resistance mutations, LIBRETTO 432 investigating peri-operative selpercatinib and novel therapeutic approaches including novel antibody drug conjugates to combat drug resistance, novel biospecific antibodies and the role of combination therapy.
Professor O’Toole reviews fusion oncogene testing technology, practices and availability in Australia, and the experts discuss technical, logistic and financial barriers to testing and expected future developments.
This program is supported by an independent and unrestricted educational grant by EliLilly
Faculty
Professor Kenneth O’Byrne, MBBS, FRACP, FRCPA, MD, Princess Alexandra Hospital
Professor Duncan Topliss, MBBS (Hons), MD, FRACP, FACE, Alfred Health
Professor Sandra O’Toole, MBBS (Hons), FRCPA, PhD, Royal Prince Alfred Hospital
Dr Malinda Itchins, BMedSci, MBBS(Hons1), PhD, FRACP, Royal North Shore Hospital
# of credits: 0 
Duration: 1 hr FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
